ClinicalTrials.gg
Not yet recruitingNCT07859943Updated Oct 8, 2026

Inspiratory Muscle Strength Training in Adults With Type 1 Diabetes

An interventional study of High-Resistance Inspiratory Muscle Strength Training and Sham Inspiratory Muscle Strength Training in Type 1 Diabetes, sponsored by Florida State University. Not yet recruiting at 2 sites in United States. Open to participants aged 18 Years to 35 Years. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Florida State University · Not applicable, Interventional, and Prevention

How we know

Updated Oct 8, 2026Eligibility revisedNewly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States — 190 open to participants now, 257 under way, 17 of them phase 3. Diabetes Mellitus, Type 1 · United States.

Planned enrollment
720th of 1,242
30 · median 40
Started
2027
with 6 others
No phase
614 of 1,458
99 open now
Primary completion
2028-09
later than 204 of 256 live
Registered
1,456th of 1,458
by date

Among the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, this one is the 720th largest by planned enrollment of the 1,242 interventional ones that give a count, is one of 7 that started in 2027, is one of 614 with no phase, reaches primary completion later than 204 of the 256 other live ones, and was the 1,456th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

190 of the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States are open now. Recruiting first, the newest first:

185 more — sign in →

All 190 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 18 Years to 35 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, or all of them as a file.
02

Study summary

Adults with type 1 diabetes have elevated cardiovascular disease risk, and systolic blood pressure is a leading modifiable contributor to that risk. Aerobic exercise lowers blood pressure but poses time and glycemic-management barriers for people with type 1 diabetes. Inspiratory muscle strength training is a brief, home-based, device-based intervention that takes about five minutes per day and has lowered systolic blood pressure in other adult populations.

This pilot trial will test whether eight weeks of daily high-resistance inspiratory muscle strength training lowers blood pressure and improves vascular function in adults with type 1 diabetes. Participants will be randomized 2:1 to high-resistance or very-low-resistance sham training using a POWERbreathe K3 device and will complete 30 training breaths per day at home for eight weeks. Outcomes are assessed before and after the training period.

Read the detailed description

Approximately two million Americans live with type 1 diabetes, and cardiovascular disease is the leading cause of death in this population. After glycemic control, systolic blood pressure is the leading modifiable cardiovascular risk factor. Traditional aerobic exercise lowers blood pressure and improves vascular function, but most adults with type 1 diabetes do not meet physical activity recommendations, citing time constraints and concern about exercise-associated hypoglycemia.

Inspiratory muscle strength training (IMST) requires about five minutes per day, is performed seated at home with a commercially available handheld device, and is unlikely to provoke hypoglycemia. A retrospective analysis of five independent trials in 128 adults reported a 9 mmHg reduction in casual systolic blood pressure following high-resistance IMST compared with sham training, with effects that appear consistent across age, sex, health status, and baseline blood pressure. No study has examined IMST in people with type 1 diabetes.

Participants are randomized in a 2:1 ratio to high-resistance IMST or very-low-resistance sham IMST. Randomization uses a computer-generated sequence held by an unmasked team member who is responsible only for setting device resistance; participants, investigators, and outcome assessors remain masked to group assignment. All participants complete approximately 56 daily training sessions over eight weeks, each consisting of five bouts of six forceful inhalations with about 30 seconds of rest between bouts.

Maximal inspiratory pressure is measured at weeks 0, 2, 4, 6, and 8. For the high-resistance group, device resistance is set to a graded percentage of the participant's current maximal inspiratory pressure: 55% during weeks 1-2, 65% during weeks 3-4, and 75% during weeks 5-8. The sham group trains at 15% of maximal inspiratory pressure throughout. Participants are debriefed on their group assignment at the end of the post-training visit.

Testing visits at week 0 and week 8 include laboratory blood pressure, brachial artery flow-mediated dilation and post-occlusion reactive hyperemia by high-resolution ultrasound, central blood pressure and arterial stiffness by applanation tonometry, and isometric handgrip exercise testing with post-exercise circulatory occlusion. Participants measure their blood pressure at home once weekly on a provided automated monitor during weeks without a laboratory visit. Brief check-in contacts occur on odd weeks and device adjustment visits on even weeks. An optional follow-up visit repeating all assessments is offered at week 12.

03

Conditions studied

  • Type 1 Diabetes

Keywords

  • inspiratory muscle strength training
  • respiratory muscle training
  • blood pressure
  • hypertension
  • vascular function
  • flow-mediated dilation
  • arterial stiffness
  • type 1 diabetes
04

Who can participate

The criteria were revised on the registry on Oct 8, 2026. See what changed

Ages eligible
18 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 to 35 years
  • Type 1 diabetes diagnosed more than 1 year before screening
  • (HbA1c) 10.0% or less within the last 3 months (may be measured at screening)- 18 to 29.9 kg/m\^2
  • Stable insulin delivery method for the past 30 days
  • Ability to read all device instructions and insulin pump settings
  • Estimated at least 60 mL/min/1.73 m\^2 within the last 3 months (may be measured at screening)
  • Use of an insulin pump or insulin delivery by multiple daily injections
  • Attendance at 3 or more diabetes care visits over the past 12 months

Exclusion criteria

Exclusion Criteria:

  • Diabetes-related hospitalization, including for diabetic ketoacidosis or severe hypoglycemia, within 12 months of screening
  • Poorly controlled hypertension, defined as systolic blood pressure at least 140 mmHg or diastolic blood pressure at least 90 mmHg
  • Taking diabetes medications other than insulin
  • Structured exercise more than 150 minutes per week for the last 3 months
  • Pregnant, lactating, or planning to become pregnant within the study period
  • Unstable weight, defined as more than 5% change in the last 3 months
  • Significant organ system dysfunction, such as severe pulmonary, renal, hepatic, or cardiovascular disease
  • Diagnosed anemia or known less than 10 g/dL
  • Diagnosed neuropathic or psychiatric illness
  • Active nicotine or illegal drug use
  • Alcohol consumption totaling more than 10 standard drinks per week
  • Unable to grant voluntary
  • Unable or unwilling to follow the study protocol
  • Per the POWERbreathe device user manual: history of spontaneous pneumothorax; a collapsed lung that has not fully healed; a pacemaker or medical implant containing magnets or electronics; any condition of the eardrum, such as a burst eardrum that has not fully healed
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    High-Resistance Inspiratory Muscle Strength Training

    Participants complete daily inspiratory muscle strength training using a POWERbreathe K3 device for eight weeks. Each session consists of five bouts of six forceful inhalations against resistance, with approximately 30 seconds of rest between bouts, for 30 training breaths per day. Resistance is set to a graded percentage of the participant's current maximal inspiratory pressure: 55% during weeks 1-2, 65% during weeks 3-4, and 75% during weeks 5-8.

    Device: High-Resistance Inspiratory Muscle Strength Training

  • Sham comparator
    Sham Inspiratory Muscle Strength Training

    Participants complete daily inspiratory muscle strength training using a POWERbreathe K3 device for eight weeks. Each session consists of five bouts of six forceful inhalations against resistance, with approximately 30 seconds of rest between bouts, for 30 training breaths per day. Resistance is set to 15% of the participant's maximal inspiratory pressure throughout the eight weeks.

    Device: Sham Inspiratory Muscle Strength Training

Interventions

  • DeviceHigh-Resistance Inspiratory Muscle Strength Training

    Daily home-based inspiratory muscle strength training using a POWERbreathe K3 device for eight weeks, at 55% of maximal inspiratory pressure during weeks 1-2, 65% during weeks 3-4, and 75% during weeks 5-8. Maximal inspiratory pressure is re-measured at weeks 0, 2, 4, 6, and 8 and resistance is adjusted accordingly.

  • DeviceSham Inspiratory Muscle Strength Training

    Daily home-based inspiratory muscle strength training using a POWERbreathe K3 device for eight weeks, at 15% of maximal inspiratory pressure throughout.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Laboratory-Measured Seated Systolic Blood Pressure at 8 Weeks

    Seated brachial systolic blood pressure measured in the laboratory with an automated oscillometric monitor after a period of quiet rest. This is the powered primary outcome.

    Time frame: Baseline and 8 weeks

Secondary outcomes

  1. Change From Baseline in Home Systolic Blood Pressure at 8 Weeks

    Self-measured seated brachial systolic blood pressure recorded at home once weekly on a provided automated monitor, following American Heart Association home-monitoring recommendations.

    Time frame: Baseline and 8 weeks

07

Study locations

2 sites
  • Cardiovascular and Applied Physiology Laboratory
    Tallahassee, Florida 32306, United States
  • Florida State University
    Tallahassee, Florida 32306, United States
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant-level data (IPD) that correspond directly to the key outcomes reported in peer-reviewed publications will be preserved and shared.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data will be made available after peer-review publication of the final dataset, but no later than 1 year after the completion of data collection. Data will remain available for a period of at least 10 years, per the University's guidelines for records retention.

Access criteria: Access will be unrestricted and open to the scientific community without controlled-access barriers. All data will be fully de-identified in compliance with HIPAA guidelines by removing direct/indirect personal identifiers and assigning coded study IDs prior to upload. Datasets will be structured in open, interoperable formats (CSV and/or TXT) requiring no specialized software to access. Datasets will be archived and publicly searchable in Zenodo (a FAIR-aligned public generalist repository) and assigned a persistent Digital Object Identifier (DOI). Summary results will also be submitted directly to ClinicalTrials.gov.

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Sep 2028, 20 months later.

Of 852 non-industry interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's planned 20 months is close to that.

Counting every sponsor, half of 957 studies reached it within 18 months; a quarter within 9 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2026
First posted
Oct 6, 2026
StartEst.
Jan 1, 2027
Primary completionEst.
Sep 1, 2028
CompletionEst.
Oct 1, 2028
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
8 inclusion criteria added, 1 removed; 14 exclusion criteria added, 1 removed
What changed in the criteria
Inclusion criteria
  • RemovedAge 18 to 35 years Type 1 diabetes diagnosed more than 1 year before screening HbA1c 10.0% or less within the last 3 months (may be measured at screening) Body mass index 18 to 29.9 kg/m\^2 Stable insulin delivery method for the past 30 days Ability to read all device instructions and insulin pump settings Estimated glomerular filtration rate at least 60 mL/min/1.73 m\^2 within the last 3 months (may be measured at screening) Use of an insulin pump or insulin delivery by multiple daily injections Attendance at 3 or more diabetes care visits over the past 12 months
  • AddedAge 18 to 35 years
  • AddedType 1 diabetes diagnosed more than 1 year before screening
  • AddedHemoglobin A1c (HbA1c) 10.0% or less within the last 3 months (may be measured at screening)- Body mass index 18 to 29.9 kg/m\^2
  • AddedStable insulin delivery method for the past 30 days
  • AddedAbility to read all device instructions and insulin pump settings
  • AddedEstimated glomerular filtration rate at least 60 mL/min/1.73 m\^2 within the last 3 months (may be measured at screening)
  • AddedUse of an insulin pump or insulin delivery by multiple daily injections
  • AddedAttendance at 3 or more diabetes care visits over the past 12 months
Exclusion criteria
  • RemovedDiabetes-related hospitalization, including for diabetic ketoacidosis or severe hypoglycemia, within 12 months of screening Poorly controlled hypertension, defined as systolic blood pressure at least 140 mmHg or diastolic blood pressure at least 90 mmHg Taking diabetes medications other than insulin Structured exercise more than 150 minutes per week for the last 3 months Pregnant, lactating, or planning to become pregnant within the study period Unstable weight, defined as more than 5% change in the last 3 months Significant organ system dysfunction, such as severe pulmonary, renal, hepatic, or cardiovascular disease Diagnosed anemia or known hemoglobin less than 10 g/dL Diagnosed neuropathic or psychiatric illness Active nicotine or illegal drug use Alcohol consumption totaling more than 10 standard drinks per week Unable to grant voluntary informed consent Unable or unwilling to follow the study protocol Per the POWERbreathe device user manual: history of spontaneous pneumothorax; a collapsed lung that has not fully healed; a pacemaker or medical implant containing magnets or electronics; any condition of the eardrum, such as a burst eardrum that has not fully healed
  • AddedDiabetes-related hospitalization, including for diabetic ketoacidosis or severe hypoglycemia, within 12 months of screening
  • AddedPoorly controlled hypertension, defined as systolic blood pressure at least 140 mmHg or diastolic blood pressure at least 90 mmHg
  • AddedTaking diabetes medications other than insulin
  • AddedStructured exercise more than 150 minutes per week for the last 3 months
  • AddedPregnant, lactating, or planning to become pregnant within the study period
  • AddedUnstable weight, defined as more than 5% change in the last 3 months
  • AddedSignificant organ system dysfunction, such as severe pulmonary, renal, hepatic, or cardiovascular disease
  • AddedDiagnosed anemia or known hemoglobin less than 10 g/dL
  • AddedDiagnosed neuropathic or psychiatric illness
  • AddedActive nicotine or illegal drug use
  • AddedAlcohol consumption totaling more than 10 standard drinks per week
  • AddedUnable to grant voluntary informed consent
  • AddedUnable or unwilling to follow the study protocol
  • AddedPer the POWERbreathe device user manual: history of spontaneous pneumothorax; a collapsed lung that has not fully healed; a pacemaker or medical implant containing magnets or electronics; any condition of the eardrum, such as a burst eardrum that has not fully healed
Oct 8, 2026
Registered
First appeared on the registry
Oct 6, 2026
Show all 2 updates
  1. Oct 8, 2026
    Eligibility 8 inclusion criteria added, 1 removed; 14 exclusion criteria added, 1 removed
    What changed in the criteria
    Inclusion criteria
    • RemovedAge 18 to 35 years Type 1 diabetes diagnosed more than 1 year before screening HbA1c 10.0% or less within the last 3 months (may be measured at screening) Body mass index 18 to 29.9 kg/m\^2 Stable insulin delivery method for the past 30 days Ability to read all device instructions and insulin pump settings Estimated glomerular filtration rate at least 60 mL/min/1.73 m\^2 within the last 3 months (may be measured at screening) Use of an insulin pump or insulin delivery by multiple daily injections Attendance at 3 or more diabetes care visits over the past 12 months
    • AddedAge 18 to 35 years
    • AddedType 1 diabetes diagnosed more than 1 year before screening
    • AddedHemoglobin A1c (HbA1c) 10.0% or less within the last 3 months (may be measured at screening)- Body mass index 18 to 29.9 kg/m\^2
    • AddedStable insulin delivery method for the past 30 days
    • AddedAbility to read all device instructions and insulin pump settings
    • AddedEstimated glomerular filtration rate at least 60 mL/min/1.73 m\^2 within the last 3 months (may be measured at screening)
    • AddedUse of an insulin pump or insulin delivery by multiple daily injections
    • AddedAttendance at 3 or more diabetes care visits over the past 12 months
    Exclusion criteria
    • RemovedDiabetes-related hospitalization, including for diabetic ketoacidosis or severe hypoglycemia, within 12 months of screening Poorly controlled hypertension, defined as systolic blood pressure at least 140 mmHg or diastolic blood pressure at least 90 mmHg Taking diabetes medications other than insulin Structured exercise more than 150 minutes per week for the last 3 months Pregnant, lactating, or planning to become pregnant within the study period Unstable weight, defined as more than 5% change in the last 3 months Significant organ system dysfunction, such as severe pulmonary, renal, hepatic, or cardiovascular disease Diagnosed anemia or known hemoglobin less than 10 g/dL Diagnosed neuropathic or psychiatric illness Active nicotine or illegal drug use Alcohol consumption totaling more than 10 standard drinks per week Unable to grant voluntary informed consent Unable or unwilling to follow the study protocol Per the POWERbreathe device user manual: history of spontaneous pneumothorax; a collapsed lung that has not fully healed; a pacemaker or medical implant containing magnets or electronics; any condition of the eardrum, such as a burst eardrum that has not fully healed
    • AddedDiabetes-related hospitalization, including for diabetic ketoacidosis or severe hypoglycemia, within 12 months of screening
    • AddedPoorly controlled hypertension, defined as systolic blood pressure at least 140 mmHg or diastolic blood pressure at least 90 mmHg
    • AddedTaking diabetes medications other than insulin
    • AddedStructured exercise more than 150 minutes per week for the last 3 months
    • AddedPregnant, lactating, or planning to become pregnant within the study period
    • AddedUnstable weight, defined as more than 5% change in the last 3 months
    • AddedSignificant organ system dysfunction, such as severe pulmonary, renal, hepatic, or cardiovascular disease
    • AddedDiagnosed anemia or known hemoglobin less than 10 g/dL
    • AddedDiagnosed neuropathic or psychiatric illness
    • AddedActive nicotine or illegal drug use
    • AddedAlcohol consumption totaling more than 10 standard drinks per week
    • AddedUnable to grant voluntary informed consent
    • AddedUnable or unwilling to follow the study protocol
    • AddedPer the POWERbreathe device user manual: history of spontaneous pneumothorax; a collapsed lung that has not fully healed; a pacemaker or medical implant containing magnets or electronics; any condition of the eardrum, such as a burst eardrum that has not fully healed
    + 2 other changes: verification date and contact details
  2. Oct 6, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07859943
Responsible party
Joseph Watso (Assistant Professor, Florida State University) — Principal investigator
First posted
Oct 6, 2026
Start date
Jan 1, 2027 (estimated)
Primary completion
Sep 1, 2028 (estimated)
Completion
Oct 1, 2028 (estimated)
Last update
Oct 8, 2026

Study contacts

Jonathan Hoch
Contact
chhs-cap@fsu.edu
8506441281
Joseph C Watso
principal investigator · Florida State University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion